Announced Mon, 6 Jul · 15:52 IST
Routine SEBI compliance certificate for share dematerialization for Q1 FY27
Compliance View source PDF
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-3.8%1-day move
₹237.90
prior close
₹235.50
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.5-0.6-0.8-1.1-3.8-2.6-2.1-3.5-5.3-5.2————
Up moveDown movePending
AI summary
Jagsonpal Pharmaceuticals filed a routine compliance certificate under SEBI Regulation 74(5) for the quarter ended June 30, 2026. The certificate from its registrar, MCS Share Transfer Agent Limited, confirms that securities received for dematerialization were listed on the stock exchanges and that the physical share certificates were duly verified, mutilated, cancelled, and replaced with demat entries in the depository.
Likely market impact
Routine procedural compliance filing. No material impact on shareholders, operations, or stock price.